For the first time since the National Council Licensure Examination was revised in 2023, the annual pass rate has decreased, according to new data from the National Council of State Boards of Nursing.

Nine years in the making, Cyanide has expanded Styx's scope in all the right ways without sacrificing its steadfast focus on stealth. PC Gamer's got your back Our experienced team dedicates many hours ...

It makes sense that Ember Lab, the developer of Kena: Bridge of Spirits, started out as an animation studio. Just looking at this gorgeous world and Pixar-esque character designs tells you that this ...

The following contains spoilers for A Knight of the Seven Kingdoms episode 5. The penultimate episode of A Knight of the Seven Kingdoms’ first season features what, by all rights, should be its most ...

The actor and Jacob Elordi play the tortured lovers from the Emily Brontë classic in this florid, overstuffed version by Emerald Fennell. By Manohla Dargis When you purchase a ticket for an ...

Adolescence writer Jack Thorne has adapted William Golding's classic novel for his latest TV series about murderous male youth – but it's a very different beast. Jack Thorne has long been an acclaimed ...

You almost have to admire the hedonism of looking at The Last of Us Remastered, which is still visually impressive eight years later, and saying, “Yeah, that looks pretty good, but we can do better.” ...

With three years spent researching, comparing, and testing software products, Tyler Webb is an expert on all things telecommunications. With work featured on GetVoIP.com, he's written over 150 ...

Carley is a writer, editor and social media professional. Before starting at Forbes Health, she wrote for Sleepopolis and interned at PBS and Nickelodeon. She's a certified sleep science coach and ...

A Prescription Drug User Fee Act target date has been set for the third quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License ...

And while you’re there, I am still waiting for anyone here to review and critique my newest contribution to the PubMed literature: Rockefeller, the Flexner Report, and the American Medical Association ...